Background--Toll-like receptor (TLR) 9 recognizes bacterial DNA, activating innate immunity, whereas it also provokes inflammation in response to fragmented DNA released from mammalian cells. We investigated whether TLR9 contributes to the development of vascular inflammation and atherogenesis using apolipoprotein E-deficient (Apoe À/À ) mice.
C hronic inflammation in the vasculature causes atherosclerosis. 1 Although multifactorial in etiology, accumulating evidence indicates that the innate immune system plays a role in the development of vascular inflammation. 2 Immune cells such as macrophages recognize structures of pathogens through Toll-like receptors (TLRs), a family of pattern recognition receptors, and activate the innate immune system for self-defense. 3 On the other hand, recent studies have revealed that macrophages can also recognize molecules derived from damaged or dead host cells as endogenous ligands though TLRs, leading to the development of chronic sterile inflammation. 4, 5 In fact, activation of the innate immune system by endogenous ligands and subsequent inflammation is involved in various diseases. [6] [7] [8] Several studies have shown that inflammation caused by TLR activation by endogenous ligands participates in the development of atherosclerosis. [8] [9] [10] Recent studies have shown the involvement of TLR9 in the pathophysiology of various diseases.
11 TLR9 expressed in endosomes recognizes exogenous DNA fragments that contain unmethylated CpG DNA and plays a role in the innate immune system. 12 In addition, recent evidence has revealed that TLR9 recognizes cell-free DNA (cfDNA) released from degenerated host tissues/cells and stimulates inflammatory cells including macrophages, provoking chronic sterile inflammation. The contribution of cfDNA-TLR9 signaling-associated inflammation is reported in several disease contexts such as autoimmune diseases and others. [13] [14] [15] [16] We previously showed that obesity-induced cfDNA released from adipocytes stimulates chronic adipose tissue inflammation and insulin resistance by stimulating macrophages through TLR9. 17 Atherosclerosis and obesity-induced adipose tissue inflammation share chronic inflammation as an underlying mechanism. 18 Previous studies have shown degeneration of vascular cells including endothelial cells and macrophages in atherosclerotic lesions, [19] [20] [21] [22] suggesting the release of cellular debris that contains various endogenous ligands for TLRs. However, the role of cfDNA-TLR9 signaling in atherogenesis remains not fully understood. In this study, we hypothesized that TLR9 activation by cfDNA released in atherosclerotic lesions promotes vascular inflammation and atherogenesis. To address our hypothesis, we induced atherosclerosis in apolipoprotein E-deficient (Apoe À/À ) mice and Tlr9-deficient Apoe À/À (Tlr9 À/À Apoe À/À ) mice. Here, we infused angiotensin II (Ang II) into both mouse strains to enhance cell death. 23, 24 We further investigated the relationship between circulating cfDNA level and coronary plaque characteristics in patients with acute myocardial infarction (MI) to obtain translational evidence for cfDNA-TLR9 signaling in atherogenesis.
Methods
The data that support the findings of this study are available from the corresponding author upon reasonable request.
Animal Experiments
Apoe À/À mice (C57BL/6J background) and Tlr9 À/À mice (C57BL/6J background) were originally purchased from the Jackson Laboratory and Oriental BioService, Inc, respectively. Tlr9 À/À Apoe À/À mice were generated by crossing Apoe À/À mice and Tlr9 À/À mice. Male mice were fed a Western-type diet (WTD; Oriental Yeast Co Ltd) from 6 weeks of age through the completion of the experiment. Ang II, 1000 ng/ kg per minute (Wako Pure Chemical Industries, Ltd, Osaka, Japan) was infused by an osmotic pump (Alzet, Cupertino, CA) from 2 weeks after starting a WTD, for 4 weeks. For in vivo TLR9 inhibition, phosphothioate-modified oligodeoxynucleotide-iODN2088 (5 0 -tcctggcggggaagt-3 0 ) was used. Control (Ctrl)-iODN2088 (5 0 -tcctgagcttgaagt-3 0 ) was used as its control. These oligodeoxynucleotides were synthesized with a low level of endotoxin (<0.5 endotoxin units/mg; Gene Design Inc., Osaka, Japan) and intraperitoneally injected into Ang IIinfused Apoe À/À mice (150 lg) three times a week for 4 weeks. All mice were housed under a 12-hour light/dark cycle, with food and water available ad libitum. All experimental procedures conformed to the guidelines for animal experimentation of Tokushima University. The protocol was reviewed and approved by our institutional ethics committee.
Bone Marrow Transplantation
Bone marrow (BM) transplantation was performed as described previously. 17 Six-week-old recipient mice were lethally irradiated (total, 9 Gy). On the following day, unfractionated BM cells harvested from donor mice were injected into recipient mice via tail-vein injection. At 2 weeks after BM transplantation, all mice were started on a WTD, and at 4 weeks after BM transplantation, Ang II infusion was started.
Clinical Perspective
What Is New?
• Angiotensin II infusion to apolipoprotein E-deficient mice (Apoe À/À ) increased circulating levels of cell-free DNA, a ligand for TLR9.
• Genetic deletion or pharmacologic blockade of TLR9 attenuated atherogenesis in angiotensin II-infused Apoe À/À mice and the activation of TLR9 promoted proinflammatory activation of macrophages.
• The plasma level of cell-free DNA collected from the target vessel in patients with acute myocardial infarction positively correlated with inflammatory features of target lesions (eg, lipid arc, macrophage content, and ruptured cavity length/ area), which were determined by optical coherence tomography.
What Are the Clinical Implications?
• Inhibiting the cell-free DNA-TLR9 axis attenuates proinflammatory activation of macrophages and vascular inflammation and might be a potential therapeutic target for atherosclerotic disease.
Replacement rate after BM transplantation was determined by fluorescence in situ hybridization of the X and Y chromosomes in male recipient mice repopulated with female BM as we described previously. 17 We used only BM chimeric mice, in which >80% of BM had been replaced by donor BM.
Atherosclerotic Lesion Analyses
Atherosclerotic lesions was examined as we reported previously. 25 In brief, mice were euthanized with an overdose of pentobarbital and perfused with 0.9% sodium chloride solution. The heart and aorta were removed immediately. The thoracic aorta was opened longitudinally, and the abdominal aorta was snap-frozen in liquid nitrogen for further analyses. The severity of abdominal aortic aneurysm was determined as reported previously. 26 Atherosclerotic lesions in the aortic arch were determined by en face Sudan IV staining. The characteristics of atherosclerotic plaques were examined in frozen sections of lesions in the aortic root (at 5-lm intervals). Lipid deposition in plaques was determined by oil red O staining. The expression of vascular cell adhesion molecule-1 (VCAM-1) and intercellular cell adhesion molecule-1 (ICAM-1), and accumulation of macrophages in plaques were examined by immunohistochemical staining. Sections were incubated with anti-VCAM-1 antibody (Abcam, Cambridge, MA), anti-ICAM-1 antibody (Abcam), or anti-Mac3 antibody (BD Biosciences, Bedford, MA), followed by the avidin-biotin complex technique and stained using a Vector Red substrate kit (Vector Laboratories, Burlingame, CA). Each section was counterstained with hematoxylin.
Electron Microscopic Analysis
For immunogold staining, samples were fixed in a 4% paraformaldehyde solution containing 0.1% glutaraldehyde and 0.05% Triton X-100 and then embedded in glycol methacrylate. Ultrathin (80-100 nm) sections were incubated with 1% bovine serum albumin in 0.01 mol/L PBS for 1 hour and rinsed with 0.01 mol/L PBS for 15 minutes. The sections were incubated overnight with anti-single-stranded DNA (ssDNA) Rabbit IgG Affinity Purify (Immuno-Biological Laboratories Co Ltd, Gunma, Japan) at 4°C. After the sections were washed with 0.01 mol/L PBS, 10-nm gold-labeled goat antirabbit IgG (BBInternational, Cardiff, UK) was applied as the secondary antibody for 2 hours at room temperature. The sections were counterstained with uranyl acetate and Reynold's lead citrate and then examined under an electron microscope (H-7600; Hitachi, Tokyo, Japan). As negative controls for the immunohistochemical procedures, substitution of an identical concentration of nonimmune IgG for the primary antibody and direct incubation in colloidal gold without the primary antibody were performed.
Metabolic Parameter Analyses
At the time of euthanasia, blood was collected into K2-EDTAcontaining tubes, and plasma was stored at À80°C until required. Plasma lipid levels were measured at LSI Medience Corporation (Tokyo, Japan). Blood pressure was measured using a tail-cuff system (BP-98A, Softron, Tokyo, Japan Real-Time Reverse-Transcription Polymerase Chain Reaction cDNA was synthesized using a QuantiTect Reverse Transcription kit (Qiagen, Venlo, the Netherlands) from total RNA extracted from tissues or cells using an illustra RNAspin RNA Isolation Kit (GE Healthcare, Chicago, IL). Quantitative realtime polymerase chain reaction (qPCR) was performed on Mx3000P (Agilent Technologies, Santa Clara, CA) using genespecific primers (Table S1 ) and Power SYBR Green PCR Master Mix (Applied Biosystems, Foster City, CA). Data are expressed in arbitrary units normalized by b-actin.
Western Blotting Analysis
Lysates prepared from cells or aorta in RIPA buffer (Wako Pure Chemical Industries, Ltd, Osaka, Japan) containing a protease inhibitor cocktail (Roche, Basel, Switzerland) and a phosphatase inhibitor cocktail (Thermo Fisher Scientific) were separated on SDS-polyacrylamide gel electrophoresis gels. The following antibodies were used: anti-TLR9, anti-VCAM-1 (Abcam, Cambridge, MA), anti-p38 MAPK, anti-phospho-p38 MAPK (Cell Signaling, Danvers, MA), and anti-b-actin (Sigma, Fukushima, Japan). Levels of expression were quantified by densitometry (ImageQuant LAS 4000mini; GE Healthcare Life Sciences, Little Chalfont, England).
Enzyme Linked Immunosolvent Assay
To detect proinflammatory activation of macrophages, we performed ELISA using culture supernatant of macrophages:
were cultured with ODN1826 or Ctrl-ODN1826 for 24 hours, and then culture supernatant was collected after centrifugation and filtration through a 20-lm mesh to remove cell debris. Levels of monocyte chemoattractant protein-1 (MCP-1) and tumor necrosis factor-a (TNF-a) in culture supernatant were measured using commercially available kit (Proteintech, Chicago, IL).
Clinical Research
We included patients with acute MI including both ST-segment elevation MI or non-ST-segment elevation MI who underwent emergency percutaneous coronary intervention and optical coherence tomography (OCT) study of the vessel undergoing percutaneous coronary intervention at Wakayama Medical University Hospital. The diagnostic criteria for these disease conditions were described in the previous study. 27 Patients with hemodynamic shock, renal insufficiency with baseline creatinine >1.6 mg/dL (or estimated glomerular filtration rate <35 mL/min per 1.73 m 2 ), known systemic inflammatory conditions requiring corticosteroid therapy, evidence of active infectious diseases, a left main coronary artery lesion, an extremely tortuous vessel, or reference vessel diameter >4 mm were excluded. In addition, we excluded patients with poor OCT images. This protocol was approved by the Wakayama Medical University Ethics Committee. All patients provided written informed consent before participation. This study was in compliance with the Declaration of Helsinki with regard to investigations on humans.
Primary percutaneous coronary intervention was performed in all patients. Coronary angiography was performed using a 5-Fr Judkins-type catheter via the femoral or radial approach. All patients received oral aspirin, an intravenous bolus injection of 5000 U heparin, and intracoronary isosorbide dinitrate before angiography. After completion of diagnostic angiography, the culprit lesion was identified on the basis of coronary angiography findings as well as those of electrocardiography and echocardiography. Before manual thromboaspiration, blood was collected from coronary arteries using an aspiration catheter (Export; Medtronic Japan, Tokyo, Japan). All samples were immediately centrifuged at 3000g for 15 minutes, and then stored at À80°C. Following thromboaspiration, frequency domain OCT (ILUMIEN and ILUMIEN OPTIS, St. Jude Medical, Minnesota, USA; or LUNAWAVE, Terumo, Tokyo, Japan) was used to observe the culprit lesion morphology. No patients were administered glycoprotein IIa/IIIb inhibitors because their use is not approved in Japan.
All OCT images were analyzed using commercially available offline OCT consoles as described previously. 27 For OCT image analysis, consensus reading was performed by 2 experienced OCT investigators (A.T. and T.N.) who were blinded to the angiographic and clinical data. Macrophages were assessed using a previously reported technique. 28 In short, macrophage accumulation was defined as high-intensity, signal-rich linear regions with sharp attenuation. Maximum lipid arc was also measured.
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The cross-sectional area of the ruptured cavity at the site of the largest intraplaque cavity and longitudinal cavity length were measured according to the previous study. 30 Four patients were excluded from the analysis of cavity area/length because clear cavity images were not obtained because of thrombi.
Statistical Analyses
All numerical values are expressed as meanAESEM. Comparison of parameters between 2 groups was performed with unpaired Student t test when data showed a normal distribution or with Mann-Whitney U test when data did not show a normal distribution. The utilized nonparametric test (Mann-Whitney) is based on ranks and thus less sensitive to the magnitude of outliers. The severity of abdominal aortic aneurysm and survival curve between the 2 strains were analyzed by Mann-Whitney U test and Kaplan-Meier method with log-rank test, respectively. Univariate analysis between plaque characteristics and plasma dsDNA or ssDNA level was performed using Spearman's rank correlation coefficient. A value of P<0.05 was considered significant.
Results

Angiotensin II Increases Circulating cfDNA in Plasma and TLR9 Expression in Atherosclerotic Aorta
To stimulate cell death and atherogenesis, we administered Ang II to animals. Ang II infusion for 4 weeks significantly elevated circulating level of dsDNA in both Apoe À/À mice and
Tlr9
À/À Apoe À/À mice, and ssDNA in Tlr9 À/À Apoe À/À mice ( Figure 1A and 1B). Ang II infusion also increased the expression of TLR9, a receptor for cfDNA, at the RNA and protein level in the atherosclerotic aorta in Apoe À/À mice ( Figure 1C and 1D ). Immunoelectron microscopic analysis using atherosclerotic plaques demonstrated accumulation of ssDNA in the cytoplasm of macrophages, suggesting that macrophages take up cfDNA in atherosclerotic lesions ( Figure 1E ).
Genetic Deletion of TLR9 in Apoe À/À Mice Attenuates Vascular Inflammation and Atherogenesis
We compared atherosclerotic lesion progression in the aortic arch between Apoe À/À mice and Tlr9
mice after 4 weeks of Ang II infusion. Blood pressure and levels of lipids such as total cholesterol, high-density lipoprotein cholesterol, and triglyceride were comparable between the two mouse strains ( Table 1 face Sudan IV staining in the aortic arch (P<0.05) ( Figure 4A ). iODN2088 did not alter metabolic parameters including blood pressure and plasma lipid levels ( Table 2 ). The results of qPCR analysis showed that iODN2088 treatment decreased the expression of inflammatory molecules, such as ICAM-1 and MCP-1, and a macrophage marker in the atherosclerotic aorta ( Figure 4B ). Histologic analyses demonstrated that inhibition of TLR9 reduced the expression of VCAM-1 (P<0.01) and macrophage accumulation (P<0.001) in atherosclerotic plaques in Apoe À/À mice. iODN2088 treatment decreased lipid deposition and ICAM-1 expression, although these did not reach statistical significance ( Figure 5A through 5D ). These results suggested that in vivo TLR9 blockade partially attenuates the development of vascular inflammation and atherosclerosis.
Restoration of TLR9 in BM Stimulates Atherogenesis in Tlr9
Immune cells such as macrophages are the major population which expresses TLR9. Therefore, to examine the role of TLR9 in atherogenesis, we restored TLR9 in BM in Tlr9 À/À Apoe À/À mice. Atherosclerotic lesion development under Ang II infusion was significantly greater in mice that express TLR9 in BM than mice that lack TLR9 in BM (P<0.05) ( Figure 6A ). We also examined the expression of inflammatory molecules in the aorta. The expression of a macrophage marker was significantly higher in the mice that have TLR9 in BM compared with the mice that lack TLR9 in BM (P<0.05). The expression of other inflammatory molecules showed the same tendency; however, it did not reach statistical significance ( Figure 6B ). There were no differences in metabolic parameters between these mice (Table 3) .
TLR9 Signaling Promotes Macrophage Activation
We investigated the role of TLR9 in macrophage activation, an essential feature of vascular inflammation and atherogenesis. TLR9 activation by ODN1826, a TLR9 agonist, promoted the expression of inflammatory molecules such as VCAM-1 and ICAM-1 in Apoe À/À macrophages, but not in Tlr9 À/À Apoe macrophages ( Figure 7A ). iODN2088, a specific antagonist of TLR9, completely inhibited these responses ( Figure S2 ). Proinflammatory activation of macrophages was also confirmed at the protein level ( Figure 7B and 7C ).
TLR9 is a receptor for DNA fragments released from degenerated cells. Therefore, we prepared gDNA from macrophages and transfected it into Apoe À/À or Tlr9
gDNA promoted inflammatory molecule (eg, VCAM-1, ICAM-1, and 
MCP-1) expression more effectively in Apoe
À/À macrophages than in Tlr9 À/À Apoe À/À macrophages ( Figure 7D ).
The results of Western blotting analysis showed that ODN1826 increased the phosphorylation of p38 MAPK in Apoe À/À macrophages ( Figure 8A and Figure S3 ). Furthermore, a p38 MAPK inhibitor, SB203580, attenuated ODN1826-induced expression of inflammatory molecules ( Figure 8B ). These results indicated that activation of MAPK signaling participates in the TLR9-mediated inflammatory response of macrophages at least partially.
Circulating cfDNA Is Associated With Plaque Vulnerability in Humans
To investigate the clinical significance of cfDNA, we examined the relationship between plaque characteristics determined by OCT and circulating cfDNA in the coronary artery in patients with acute MI. The patients' background is summarized in iODN2088, an inhibitory oligonucleotide for TLR9, to Ang II-infused Apoe À/À mice reduced atherosclerotic lesion development compared with control oligonucleotide administration, CtrliODN (n=7-8). Bar: 1 mm. B, qPCR analysis using abdominal aorta revealed that iODN2088 treatment decreased the expression of inflammatory molecules such as VCAM-1, ICAM-1, and MCP-1. TLR9 deletion also reduced the expression of F4/80, a macrophage marker, and TNF-a in the atherosclerotic aorta (n=7-8). *P<0.05 and **P<0.01. All comparisons between iODN2088-treated group and Ctrl-iODN-treated group were performed with Mann-Whitney U test. All values are meanAESEM. ICAM-1 indicates intercellular cell adhesion molecule-1; MCP-1, monocyte chemoattractant protein-1; qPCR, quantitative real-time polymerase chain reaction; TLR9, Toll-like receptor 9; TNF-a, tumor necrosis factor-a; VCAM-1, vascular cell adhesion molecule-1.
Discussion
Accumulating evidence suggests that atherosclerosis is a chronic inflammatory disease 1 ; however, the mechanism of vascular inflammation and atherogenesis is not fully understood. In this study, we demonstrated that Ang II treatment increased the level of plasma cfDNA, an endogenous ligand for TLR9. Also, genetic deletion of TLR9 or pharmacologic blockade of TLR9 revealed that TLR9 plays a pivotal role in the development of vascular inflammation and atherogenesis in Ang II-infused Apoe À/À mice. On the other hand, restoration of TLR9 in BM promoted atherogenesis in TLR9-deficient mice. Results of in vitro experiments showed that TLR9 activation promotes proinflammatory activation of macrophages via p38 MAPK at least partially, supporting the results of our in vivo studies. Furthermore, in our clinical study, circulating cfDNA level in the coronary artery was associated with vulnerable features of atherosclerotic plaques in the coronary artery. These results suggested the participation of cfDNA-TLR9 signaling in the development of vascular inflammation and atherosclerosis. TLR activation by endogenous ligands released as damageassociated molecular patterns in response to various risk factors has attracted much attention as a possible mechanism of vascular inflammation and atherosclerosis. 9, 15 For example, previous studies have reported that activation of TLR2 or TLR4 by their endogenous ligands, such as fatty acids, lipoproteins, and heat shock proteins, promotes atherogenesis. [31] [32] [33] Recent studies including our own have suggested that TLR9 recognizes cfDNA as an endogenous ligand, promoting chronic inflammation. 11, 16, 17 However, the role of TLR9 in atherogenesis is still controversial.
In the present study, we found that Ang II infusion into Apoe À/À mice increased the expression of Tlr9 in the aorta.
Also, immunoelectron microscopic analysis demonstrated the accumulation of ssDNA in macrophages in atherosclerotic lesions. Therefore, to test the hypothesis that the cfDNA-TLR9 pathway plays a pivotal role in the progression of vascular inflammation in vivo, we employed 3 mouse models. In addition, we infused Ang II into animals to enhance vascular damage, which accelerates release of cfDNA. 23, 24 In fact, Ang II infusion increased plasma cfDNA in both mouse strains. 19 whereas recent studies also demonstrated degradation of macrophages in lesions, which is associated with the progression or vulnerability of atherosclerotic plaques. 22 gDNA more strongly promoted inflammatory molecule expression in Apoe À/À macrophages than in Tlr9 À/À Apoe À/À macrophages. We also found that TLR9 activation increased the phosphorylation of p38 MAPK signaling, an important pathway for inflammatory activation, 36, 37 in Apoe À/À macrophages. This result is consistent with previous studies demonstrating a link between TLR9 and MAPK. 38 In fact, a p38 MAPK inhibitor attenuated the expression of inflammatory molecules induced by a TLR9 agonist in Apoe À/À macrophages. These results suggested TLR9. 39, 40 The results of our present study are consistent with previous studies and provide the mechanism for TLR9 activation in atherosclerosis partially. On the other hand, a recent study by Koulis et al demonstrated antiatherogenic roles of TLR9 by using a genetic deletion model of TLR9 in Apoe À/À mice. 41 In that study, not only genetic deletion but also administration of ODN1668, another TLR9 agonist, inhibited atherosclerotic lesion development in Apoe À/À mice on a WTD. In that study, atherosclerosis was induced by long-term WTD feeding but not Ang II. While, in our present study, we infused Ang II to enhance cellular damage and in fact, cfDNA, potential TLR9 ligands, levels increased in Ang IIinfused animals. A previous study suggested different roles of TLR9 activation according to the concentration of its ligand. 42 The difference in levels of TLR9 ligands attributable to the use of different mouse models might be one of the reasons for the discrepancy. Also, in the study by Koulis et al, total cholesterol was higher in Tlr9
with an unknown mechanism; however, in the present study, there was no difference in plasma lipid levels between Apoe À/À mice and Tlr9 À/À Apoe À/À mice. This might contribute to the discrepancy. Similar to that study, in this study, Tlr9 À/À Apoe À/À mice had larger atherosclerotic lesions compared with Apoe À/À mice under vehicle infusion condition, although blood lipid levels were equivalent between 2 strains of mice ( Figure S4 and Table S2 ). Thus, we speculate that the role of TLR9 in the development of vascular inflammation and atherogenesis may differ according to the disease conditions. However, in addition to in vivo studies, in our present study, we demonstrated a proinflammatory role of TLR9 in macrophage activation, which supports our in vivo data. These results suggest the proatherogenic roles of cfDNA-TLR9 signaling, at least in an Ang II-infused condition. Further studies are needed to elucidate the contribution of cfDNA-TLR9 signaling to atherogenesis and its mechanism. Finally, in this study, we examined the association between plasma cfDNA level and plaque characteristics determined by OCT in patients with acute MI who underwent percutaneous coronary intervention. OCT is a high-resolution imaging technique for plaque characterization, 29 and allows us to assess the features of vulnerable plaques, which are associated with the inflammatory process in the vasculature. 43 A previous study showed that patients with severe coronary artery disease as assessed by coronary computed tomographic angiography have higher plasma dsDNA level, Figure 9 . Plasma cfDNA levels positively correlate with inflammatory features of coronary atherosclerosis. Plasma dsDNA or ssDNA level in the target coronary artery positively correlated with inflammatory features of coronary atherosclerosis, such as lipid arc (A and E) and macrophage grade (B and F) determined by OCT (n=39). Plasma dsDNA or ssDNA level in the target coronary artery also showed a positive correlation with cavity area (C and G) or length (D and H) in ruptured coronary artery plaques (n=35). Univariate analysis between plaque characteristics and plasma dsDNA or ssDNA level was performed using Spearman's rank correlation coefficient. cfDNA indicates cellfree DNA; dsDNA, double-stranded DNA; OCT, optical coherence tomography; ssDNA, single-stranded DNA.
suggesting inflammatory properties of released DNA fragments. 44 In this study, we further demonstrated that the plasma level of cfDNA collected from the target vessel in acute MI patients positively correlated with lipid arc, macrophage content, and ruptured cavity length/area, all of which are associated with plaque inflammation. Furthermore, a previous study demonstrated the expression of TLR9 in atherosclerotic lesions in humans. 10 Therefore, the results of our clinical study suggested that cfDNA-TLR9 signaling contributes to the development of vascular inflammation in humans, at least partially. Recent studies demonstrated that other DNA sensors may contribute to the pathophysiology of various inflammatory diseases. Therefore, an inflammatory process mediated by other DNA sensors may also be involved in the development of vascular inflammation in the coronary artery. Further studies are required to elucidate the role of DNA sensors such as TLR9 in atherogenesis. Recent studies have suggested that damage-associated molecular patterns contribute to the development of chronic inflammatory diseases as endogenous ligands that activate the innate immune system. 5 The present study demonstrated that TLR9, originally known as a sensor for exogenous DNA fragments, contributes to proinflammatory activation of macrophages and the development of vascular inflammation and atherosclerosis in Apoe À/À mice that receive Ang II infusion. In addition, the results of our clinical study suggested that cfDNA positively correlates with the features of plaque inflammation in patients with acute MI. Thus, the cfDNA-TLR9 axis participates in the pathogenesis of vascular inflammation and atherogenesis and, might be a therapeutic target for atherosclerotic disease. Table S1 . Primer sequences. qPCR analysis demonstrated that iODN2088, an inhibitory oligonucleotide for TLR9, blocked inflammatory molecule expression induced by ODN1826. *P < 0.05. All comparisons between iODN2088-treated group and Ctrl-iODN-treated group were performed with Mann-Whitney U test. All values are mean ± SEM. 
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